Welcome to our dedicated page for Callan JMB SEC filings (Ticker: CJMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Callan JMB Inc. filings document the public-company record of a Nevada corporation operating in healthcare logistics, cold-chain fulfillment, emergency preparedness support and pharmaceutical supply-chain services. The company’s Form 8-K reports furnish operating results, business updates, Regulation FD investor materials, material agreements and amendments to common stock purchase arrangements.
Registration statements describe the company’s securities offering, business disclosures, capital structure and risk factors. Proxy materials cover annual-meeting procedures, stockholder voting matters and governance. Recent current reports also document Nasdaq continued-listing compliance matters, including disclosures related to the stockholders’ equity standard for The Nasdaq Capital Market.
Callan JMB Inc. reported a weaker first quarter of 2026 with revenue of $1,106,143, down 24% from the prior year, as a key government contract was not renewed and non-government sales declined. Gross profit fell to $427,235, while selling, general and administrative expenses rose 15% to $2,128,423, driven by higher payroll, new office rent, consulting and public-company costs.
The company’s net loss widened to $3,215,054 (loss of $0.59 per share) compared with $1,240,590 a year earlier, reflecting both operating losses and $1,177,223 of ELOC-related transaction expenses plus a $338,229 loss from changes in the fair value of its ELOC derivative liability.
At March 31, 2026, cash stood at $1,415,566 and stockholders’ equity was $1,599,533, below the $2,500,000 minimum required by Nasdaq. After quarter-end, Nasdaq notified the company of this equity deficiency. Management highlights access to an Equity Line of Credit with $23.45M remaining availability and ongoing support from its CEO as key liquidity sources, and believes its plans alleviate substantial doubt about continuing as a going concern over the next twelve months.
Callan JMB Inc disclosure: Bard Associates, Inc. amended a Schedule 13G/A to report beneficial ownership of 239,266 shares of Common Stock (CUSIP 131100109), representing 4.3% of the class. The filing shows shared dispositive power over those shares; voting power is reported as zero.
Callan JMB Inc. received a Nasdaq notice that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity to remain on The Nasdaq Capital Market. The company has 45 days, until May 22, 2026, to submit a plan to regain compliance and, if Nasdaq accepts the plan, may receive up to 180 days from the notice date, until October 4, 2026, to demonstrate compliance. Trading of its common stock under the symbol CJMB continues for now, but there is no assurance the plan will be accepted or that compliance will be restored.
Callan JMB Inc., a Nevada-based cold chain logistics and fulfillment company serving the life sciences industry, reports its annual business results for the year ended December 31, 2025. The company posted a net loss of $7,966,366 and had an accumulated deficit of $10,260,014 as of year end.
Callan JMB provides temperature-controlled packaging, emergency response logistics, and remote monitoring through its Ship2Q and Sentry platforms, targeting applications such as cell therapies, vaccines, diagnostics and other biologics. Its business is capital intensive and operates under a rent-to-rent warehouse model, which requires significant upfront investment in leased and renovated facilities.
The company highlights high customer concentration, with its top three customers contributing about 79% of 2025 revenue, and notes revenue pressure from one major customer temporarily suspending orders and another significantly reducing operations. As of March 25, 2026, Callan JMB had 5,627,368 common shares outstanding and employed 20 people.
Callan JMB Inc. reported full-year 2025 results with revenue of $5.7 million, down from $6.6 million in 2024 as some state and local governments reduced demand for emergency preparedness services. Gross profit was $2.1 million versus $2.6 million a year earlier.
Selling, general and administrative expenses rose to $8.6 million from $4.8 million, largely tied to costs of its initial public offering and becoming a public company, leading to a wider operating loss of $7.0 million and net loss of $8.0 million. The company ended 2025 with $2.1 million in cash, supported by IPO and equity line proceeds, and highlighted new partnerships in pharmaceutical logistics, expanded emergency preparedness contracts, and entry into food sampling and international healthcare logistics.
CALLAN JMB INC. Chief Medical Officer David J. Croyle reported an open-market purchase of 10,195 shares of common stock at $1.75 per share on behalf of a rollover IRA. After this transaction, his indirect holdings reported in the filing total 800,000 shares, indicating a modest increase in his existing position.
Callan JMB Inc. has amended its existing Common Stock Purchase Agreement with Hexstone Capital, which allows the company to sell common stock to this investor over time. The amendment extends the maturity date to April 1, 2027, giving a longer window to use this equity facility.
The regular purchase price is now set at 95% of the lowest daily trading price during each measurement period, or 75% if the stock is suspended or delisted from its principal market. The measurement period begins when Hexstone receives a purchase notice and runs at least five trading days, ending once market trading volume reaches five times the purchase amount.
The investor’s resale “leak-out” cap is revised to the greater of $25,000 per trading day or 20.0% of that day’s trading volume. Shares issued under this arrangement remain covered by an effective Form S-1 registration statement, and the company plans to file a prospectus supplement describing these updated terms.
CALLAN JMB INC. Chief Medical Officer and 10% owner David J. Croyle reported an indirect open-market purchase of 14,805 shares of Common Stock at $1.762 per share through a Rollover IRA on March 6, 2026. Following this transaction, his indirect holdings total 789,805 shares, making this a relatively small addition to an already substantial position.
Bard Associates, Inc. has filed an amended Schedule 13G reporting beneficial ownership of 245,682 shares of CALLAN JMB INC. common stock, representing 5.3% of the outstanding class. This reflects Bard’s status as a significant institutional holder of the company’s shares.
The event date for this ownership position is listed as 12/04/2025. Bard reports no sole voting or dispositive power over the stock, but has shared dispositive power over all 245,682 shares. It certifies the shares are held in the ordinary course of business and not to influence control of the issuer.
Callan JMB Inc. filed a current report to inform investors that it will begin using a new investor presentation starting January 28, 2026 at the DealFlow Discovery Conference. The same presentation may also be used later with potential investors, industry analysts and other audiences.
The investor presentation is available on the company’s website in the Investor Relations section and is attached as Exhibit 99.1. The company notes that this information is being furnished under Regulation FD and, unless specifically stated otherwise, will not be treated as “filed” for liability purposes under the securities laws.